Vincristine liposomal - Spectrum Pharmaceuticals

Drug Profile

Vincristine liposomal - Spectrum Pharmaceuticals

Alternative Names: Marqibo; Sphingosomal vincristine; Vincacine; Vincristine sulfate injection; Vincristine sulfate liposomes injection; VSLI

Latest Information Update: 18 Jan 2016

Price : $50

At a glance

  • Originator Inex Pharmaceuticals Corporation
  • Developer CASI Pharmaceuticals; Hana Biosciences; Inex Pharmaceuticals Corporation; Spectrum Pharmaceuticals; Talon Therapeutics; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Vinca alkaloids
  • Mechanism of Action Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma; Acute lymphoblastic leukaemia
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Acute lymphoblastic leukaemia
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Acute lymphoblastic leukaemia
  • Phase III Non-Hodgkin's lymphoma
  • Phase I/II Cancer
  • Preclinical Multiple myeloma
  • Discontinued Colorectal cancer; Malignant melanoma; Pancreatic cancer; Small cell lung cancer

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 12 Jan 2016 Preregistration for Acute lymphoblastic leukaemia in Hong Kong, Taiwan, Macau, China (IV)
  • 11 Jan 2016 Servier in-licenses vincristine liposomal from Spectrum Pharmaceuticals in Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top